3 151

Cited 74 times in

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

DC FieldValueLanguage
dc.description.abstractBACKGROUND: The advent of targeted therapies in the past 7 years has extended median survival for metastatic renal-cell carcinoma. This improvement in clinical outcome has created a need for new, more accurate prognostic measures. We assessed the use of conditional survival--a measure that accounts for elapsed time since treatment initiation--for prognostication in patients with metastatic renal-cell carcinoma treated with first-line VEGF-targeted therapies. METHODS: We obtained data for patients with metastatic renal-cell carcinoma who were treated with a first-line VEGF-targeted therapy between April 7, 2003, and Oct 12, 2010, from our large multi-institutional International mRCC Database Consortium (centres in Canada, the USA, Singapore, Denmark, and South Korea). All histologies, performance statuses, and prognostic risk groups were included. The primary outcome was 2-year conditional survival, defined as the probability of surviving an additional 2 years from a given timepoint since the start of targeted therapy. Secondary analyses included 1-year and 3-year conditional survival, along with stratification of patients by Heng prognostic risk criteria and Karnofsky performance score, and conditional survival based on length of time on therapy. We used the Kaplan-Meier method and a landmark analysis to calculate conditional survival. FINDINGS: In the 1673 patients analysed, median follow-up for alive patients was 20·1 months (IQR 9·0-34·4). We recorded an increase in the 2-year conditional survival probability from 44% (95% CI 41-47) at 0 months to 51% (46-55) at 18 months since beginning targeted therapy. When stratified by the Heng prognostic risk criteria defined at therapy initiation, 2-year conditional survival changed little in the favourable and intermediate groups, but in the poor-risk group, 2-year conditional survival improved from 11% (8-15) at 0 months to 33% (18-48) after 18 months. When conditioned on time on targeted therapy from 0 months to 18 months, 2-year conditional survival improved from 44% (41-47) to 68% (60-75) in the overall population and from 74% (68-79) to 90% (77-96) in the favourable group, 49% (45-53) to 57% (45-67) in the intermediate group, and 11% (8-15) to 73% (43-89) in the poor risk group. INTERPRETATION: Conditional survival is a clinically useful prediction measure that adjusts prognosis of patients with metastatic renal-cell carcinoma on the basis of survival since treatment initiation or therapy duration. Conditional survival might be especially relevant to adjust prognosis for poor-risk patients. FUNDING: The Trust Family Fund for Kidney Cancer Research.-
dc.relation.isPartOfLancet Oncology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Renal Cell/drug therapy*-
dc.subject.MESHCarcinoma, Renal Cell/mortality*-
dc.subject.MESHCarcinoma, Renal Cell/secondary-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHKidney Neoplasms/drug therapy*-
dc.subject.MESHKidney Neoplasms/mortality*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHReceptors, Vascular Endothelial Growth Factor/antagonists & inhibitors*-
dc.subject.MESHSurvival Rate-
dc.titleConditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorLauren C Harshman-
dc.contributor.googleauthorWanling Xie-
dc.contributor.googleauthorGeorg A Bjarnason-
dc.contributor.googleauthorJennifer J Knox-
dc.contributor.googleauthorMary MacKenzie-
dc.contributor.googleauthorLori Wood-
dc.contributor.googleauthorSandy Srinivas-
dc.contributor.googleauthorUlka N Vaishampayan-
dc.contributor.googleauthorMin-Han Tan-
dc.contributor.googleauthorSun-Young Rha-
dc.contributor.googleauthorFrede Donskov-
dc.contributor.googleauthorNeeraj Agarwal-
dc.contributor.googleauthorChristian Kollmannsberger-
dc.contributor.googleauthorScott North-
dc.contributor.googleauthorBrian I Rini-
dc.contributor.googleauthorDaniel YC Heng-
dc.contributor.googleauthorToni K Choueiri-
dc.subject.keywordCarcinoma, Renal Cell/drug therapy*-
dc.subject.keywordCarcinoma, Renal Cell/mortality*-
dc.subject.keywordCarcinoma, Renal Cell/secondary-
dc.subject.keywordFollow-Up Studies-
dc.subject.keywordKaplan-Meier Estimate-
dc.subject.keywordKidney Neoplasms/drug therapy*-
dc.subject.keywordKidney Neoplasms/mortality*-
dc.subject.keywordMiddle Aged-
dc.subject.keywordReceptors, Vascular Endothelial Growth Factor/antagonists & inhibitors*-
dc.subject.keywordSurvival Rate-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.identifier.bibliographicCitationLancet Oncology, Vol.13(9) : 927-935, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.